BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene – BeiGene LTD

BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene

Jul 05, 2017 9:15 PM

CAMBRIDGE, Mass. and BEIJING, China, July 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will host a conference call and live webcast to discuss its global strategic collaboration with Celgene.

Investor Conference Call Details

Date & Time: Thursday, July 6, 2017, 9:00 AM EDT, 9:00 PM China Standard Time

Dial-in Numbers: 1-845-675-0437 or 1-866-519-4004 (US), 400-620-8038 or 800-819-0121 (China), +852 30186771 (Hong Kong), or +65 67135090 (International)

Conference ID Number: 49231438

A live webcast and replay will be available on BeiGene’s investor website, http://ir.beigene.com/. The dial-in replay will be available approximately two hours after the conference and will be available for two days following the event. It can be accessed by dialing 1-646-254-3697 (US), 400-632-2162 (China), +852 30512780 (Hong Kong), or +61 2 8199 0299 (International).

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com 

Primary Logo

Source: BeiGene, LTD.